43 results about "Hydroxycarbamide" patented technology

The present invention describes a method for producing an antibody in Pichia pastoris, such as by fed-batch fermentation. The method includes the addition of about 2.0-5.0 g / L of hydroxyurea during the fermentation process to sustain a constant cell density and enhance the whole broth titer of the antibody. The method may also include a strategy of increasing the ethanol concentration to about 18-22 g / L and then maintaining the ethanol level at about 5-17 g / L to stabilize the cell mass and enhance the production rate of the antibody. The method may further include a respiratory quotient control for monitoring the ethanol profile and to improve the quality of the antibody by, for example, eliminating clipping of the heavy chain.

The present invention relates to the use of hydroxycarbamide (HC) for reducing and / or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

The invention discloses a hydroxylamine analysis method in a coexistence of amino hydroxyl urea. The method comprises the following steps of neutralizing and diluting a to-be-detected amino hydroxyl urea coexisting sample, then putting into a volumetric flask, adding a nitrobenzaldehyde solution, then carrying out constant volume and evenly shaking by using an acetic acid solution, and standing atroom temperature; then, analyzing the to-be-detected sample by using a method for combining a high performance liquid chromatography column and an ultraviolet detector so as to obtain the peak area of hydroxylamine, and calculating to obtain the concentration of hydroxylamine in the to-be-detected sample by using a standard working curve of hydroxylamine. The lowest detecting concentration of hydroxylamine can reach 2 * 10 <-7> mol / L, and the relative standard deviation of the analysis method of the embodiment is 0.8%. According to the method, chemical derivatization - liquid chromatography method is established to analyze hydroxylamine, and analysis of hydroxylamine is not influenced by liquid chromatography method, the method is simple to operate, high in sensitivity and good in repeatability.

The invention relates to a functionalized inorganic fluorescent microsphere based on nitrogen-doped carbon quantum dots and a preparation method thereof, and the preparation method comprises the following steps: carrying out heating reaction on a heating reaction product of Chinese cabbage juice, ammonia water, urea, diethylenetriamine or polyethylene polyamine to prepare nitrogen-doped carbon quantum dots NCDs, and reacting with NaCl, urea and formaldehyde to obtain a urea-formaldehyde resin fluorescent microsphere. And reacting with ethanol and tetraethoxysilane to obtain the hydroxyurea-formaldehyde resin fluorescent microspheres. The green and non-toxic Chinese cabbage carbon quantum dots are prepared by adopting a simple and feasible method, and better fluorescence performance is presented after nitrogen doping; the hydroxyl urea-formaldehyde resin fluorescent microspheres are obtained by applying the hydroxyl urea-formaldehyde resin as a fluorescent probe to preparation of the fluorescent microspheres, and the hydroxyl urea-formaldehyde resin fluorescent microspheres have the advantages of good monodispersity, rich functional group content, easy combination with biomolecules, good biocompatibility and low toxicity, and have good application prospects in the fields of biology and medicine.

The present invention describes a method for producing an antibody in Pichia pastoris, such as by fed-batch fermentation. The method includes a respiratory quotient control for monitoring the ethanol profile and to improve the quality of the antibody by, for example, eliminating clipping of the heavy chain. The method may also include a strategy of increasing the ethanol concentration to about 18-22 g / L and then maintaining the ethanol level at about 5-17 g / L to stabilize the cell mass and enhance the production rate of the antibody. The method may also include the addition of about 2.0-5.0 g / L of hydroxyurea during the fermentation process to sustain a constant cell density and enhance the whole broth titer of the antibody.

The invention provides a multiple target point type Tamibarotene derivative as well as a preparation method and an application thereof. Particularly, RAR (retinoic acid receptor) agonist Tamibarotene is connected with antineoplastic drug hydroxycarbamide, fluorouracil and lenalidomide on sales through ester bonds or amido bonds respectively to obtain three multiple target point mutual prodrugs. The invention provides a method for preparing the compound and the application of the compound in preparing antineoplastic drugs, particularly drugs for curing various leukemias. The invention further relates to a drug combination of the compound.

The invention discloses a fusarium oxysporum f.sp.niveum RNAi component FonDCL1 gene deletion mutant and a construction method thereof. According to the fusarium oxysporum f.sp.niveum RNAi component FonDCL1 gene deletion mutant and the construction method thereof, according to a reported Dicer like 1 protein sequence, homologous alignment is conducted on a Fon genomic sequence to obtain a fusariumoxysporum f.sp.niveum FonDCL1 gene, by adopting a homologous gene substitution principle, by means of a Split-marker strategy, the target gene FonDCL1 is substituted for a hygromycin B (HPH) gene DNAfragment, and by constructing a homologous gene recombinant fragment, through genetic transformation of a wild strain Fon1, the FonDCL1 gene deletion mutant is obtained. The FonDCL1 mutant has the advantages that the virulence to watermelon seedlings is enhanced, and the FonDCL1 mutant is more sensitive to abiotic stress factors of monensin sodium salt, hydroxycarbamide, a fluorescent whitening agent CFW, Congo red (CR), hydrogen peroxide and the like, so that a research foundation is provided for functional assignment of small RNA generated in processes of self growth and development and watermelon infection of the Fon1.

The present invention relates to a pharmaceutical composition for treating cancer, comprising an anti-cancer virus, an immune checkpoint inhibitor, and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer according to the present invention comprises an anti-cancer virus, an immune checkpoint inhibitor, and hydroxyurea as active ingredients, and has excellent anti-cancer effect and safety compared to conventional cases in which the anti-cancer virus is administered alone or in combination with the anti-cancer virus and the immune checkpoint inhibitor. Therefore, the pharmaceutical composition for treating cancer of the present invention, comprising an anti-cancer virus, an immune checkpoint inhibitor, and hydroxyurea as active ingredients, can be effectively used for treating cancer.